TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TG Therapeutics secures FDA approval for BRIUMVI, poised for growth

TG Therapeutics' Q4 2022 performance reflects a solid financial position with a focus on efficient capital management and commercial execution.
Strengths lie in FDA approval for BRIUMVI, positive launch progress, and commitment to supporting the MS community, positioning the company for growth.
Challenges include sustaining momentum, achieving broad payer coverage, managing expenses, and navigating complexities related to clinical trials.
Opportunities exist in further data analysis, market expansion, community engagement, and strategic investments, driving future growth and differentiation.

TG Therapeutics excels with BRIUMVI launch, eyes European expansion

TG Therapeutics demonstrated strong financial stability and strategic expense management in Q1 2023, despite reporting a net loss, showcasing resilience and efficient operations.
BRIUMVI's early success in the US market, positive feedback from healthcare providers, and progress in payer coverage position the product as a competitive and promising offering in the MS treatment class.
While facing decisions on international expansion and expense optimization, TG Therapeutics remains committed to serving the MS community and improving patient outcomes with BRIUMVI.
The company's focus on market access, product efficacy, and financial prudence sets a solid foundation for future growth and success in the competitive pharmaceutical landscape.

TG Therapeutics reports stellar Q2 performance and eyes global expansion

TG Therapeutics showcased robust financial performance and market acceptance of Briumvi in Q2 2023.
While facing challenges like revenue lag and potential market competition, the company remains well-positioned.
Opportunities lie in expanding market reach, product offerings, and maximizing the potential of Briumvi.
Overall, TG Therapeutics' strategic partnerships and positive market feedback position it for continued success.

TG Therapeutics excels in Q3 with BRIUMVI's market success

TG Therapeutics had a strong Q3 performance, driven by BRIUMVI's success and revenue exceeding expectations. The company is well-positioned with a healthy cash reserve and plans for market expansion. Challenges include potential competition from BTK drugs and seasonal market fluctuations.

TG Therapeutics excels in Q4 with BRIUMVI, eyes strong growth

TG Therapeutics demonstrated robust financial performance and strategic growth plans during the Q4 2023 earnings call, driven by the successful launch of BRIUMVI.
While facing challenges such as optimizing the infusion process and managing expenses, the company's focus on innovation and market expansion positions it for future success.
With a strong emphasis on commercialization, patent protection, and revenue targets, TG Therapeutics shows promising potential for sustained growth and value creation.

TG Therapeutics reports robust Q1 results, eyes growth opportunities

TG Therapeutics' Q1 performance reflects strong revenue growth driven by Briumvi's success and strategic investments in awareness and commercialization.
While facing challenges in market share growth and profitability, the company's focus on innovation and partnerships positions it well for future opportunities.
Maintaining a healthy financial position and a commitment to R&D underscore TG Therapeutics' resilience and potential for continued growth in the autoimmune therapy space.

TG Therapeutics excels in Q2, raises guidance and focuses on growth

TG Therapeutics delivered a strong Q2 performance with notable achievements in sales, R&D, and financial stability. While facing challenges related to internal controls and VA contract impact, the company is well-positioned to capitalize on opportunities for growth through market expansion and strategic initiatives.

TG Therapeutics reports robust Q3 earnings and outlines growth strategies

TG Therapeutics (TGTX) delivered a strong performance in Q3 2024, driven by the success of BRIUMVI and strategic growth initiatives.
While facing challenges in market competition and product development, TGTX remains focused on innovation, expansion, and maximizing shareholder value.
The company's financial strength, successful partnerships, and clear growth strategies position TGTX for continued success and future growth in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29 – March 2, 2024, in West Palm Beach, Florida. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentations are outlined below.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Precision Biosciences

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today received an upfront cash payment and equity investment from TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indicat.

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

BRIUMVI sets the standard for CD20 administration with efficient twice-yearly 1-hour infusions. BRIUMVI should remain competitive with subcutaneous formulations.

TG Therapeutics: Inferred Expectations Point To Undervalued Shares

TG Therapeutics CEO Mike Weiss recently presented at the J.P. Morgan Healthcare Conference, sharing positive updates on Briumvi's Q4 2023 net sales and revenue guidance for 2024. 2024 revenue guidance and the expense guidance suggest the company should become cash flow positive and profitable in the second half of the year. The company plans to start human trials for a subcutaneous version of Briumvi, aiming to improve convenience and compete with other treatments.

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Sales of a new multiple sclerosis drug from TG Therapeutics crushed analysts' expectations, and TGTX stock surged in early trades Wednesday.

TG Therapeutics Adds To Its 225% Sprint After MS Drug Crushes Sales Estimates

Shares of TG Therapeutics Inc (NASDAQ: TGTX) opened 11% up on Wednesday after the biopharmaceutical firm said it sees a meaningful increase in its revenue from Briumvi this year. TG Therapeutics issues outlook for 2024 The Nasdaq-listed firm is expected to have concluded 2023 with about $89 million in U.S.

TG Therapeutics stock popped 11% on Wednesday: here's why

TG Therapeutics Inc.'s stock TGTX, -1.36% rallied 11% early Wednesday, after the biotech said it's entered an agreement with microcap Precision BioSciencies Inc. DTIL, +10.10% to acquire a worldwide license to that company's Azercabtagene Zapreleucel, or azer-cel, a CAR T cell therapy program for autoimmune diseases and other non-oncology indications. “Azer-cel is an allogeneic (off the shelf) CAR T program and the Company has near-term plans to evaluate the program in multiple autoimmune indications, with an investigational new drug (IND) filing targeted for mid-2024,” TG Therapeutics said in a statement.

TG Therapeutics agrees to purchase a global license to a Car T cell therapy program for autoimmune diseases

Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), “the Company,” today announced that it has entered into an agreement with Precision BioSciences, Inc. (NASDAQ GS: DTIL) to acquire a worldwide license to Precision's Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications. Azer-cel is an allogeneic (off the shelf) CAR T program and the Company has near-term plans to evaluate the program in multiple autoimmune indications, with an investigational new drug (IND) filing targeted for mid-2024.

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced completion of a strategic transaction with TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications ou.

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 42nd Annual J.P.

TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

TG Therapeutics (NASDAQ: TGTX) stock price continued its recovery after the company published strong financial results. The shares jumped to the psychologically important level of $15, its highest point since April 23rd.

TGTX stock price Has the TG Therapeutics train left the station?

TG Therapeutics' Q3'23 net sales of Briumvi of $25.1M seemed to impress the market. Q3'23 sales of Briumvi were aided by J-code availability and increases in payor coverage. Q4'23 sales are hard to predict but given the size of the anti-CD20 market in multiple sclerosis patients, it is unlikely Briumvi sales will top out soon.

TG Therapeutics: Trying To Fill The Gap Back To $20

Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ET Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ET

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does TG Therapeutics (TGTX) Have the Potential to Rally 127.76% as Wall Street Analysts Expect?

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, President, and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Edward White - H.C. Wainright Roger Song - Jefferies Mayank Mamtani - B.

TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference, being held at the JW Marriott Essex House, in New York City on November 6 -7, 2023.

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

The company reported Q3 results that were much better than expected. An up-front licensing payment from Neuraxpharm was a big factor in these surprisingly good results.

Why TG Therapeutics Stock Is Crushing It Today

TG Therapeutics Inc (NASDAQ:TGTX) stock is soaring today, after the biopharmaceutical name's third-quarter results smashed analyst expectations.

Biopharmaceutical Stock Soars on Earnings Beat

Shares of TG Therapeutics Inc. blasted off in very active trading Wednesday, after the biopharmaceutical company reported third-quarter results that were multiples above what was expected, as adoption of its multiple sclerosis treatment Briumvi “continues to grow.”

TG Therapeutics' stock rockets after blowout earnings

Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment received from Neuraxpharm

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET

TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

TG Therapeutics' shares have been declining since the disappointing Q2 earnings report and the Neuraxpharm deal. The launch trajectory of Briumvi has been difficult to estimate accurately, and I am revising the revenue estimate range provided in my previous article. CEO Weiss made a strong effort to lower market expectations ahead of the Q3 report and that contributed to the poor share price performance.

News for TG Therapeutics Stock (TGTX)